Santamed LT, UAB - financials and debts

Company age: 9 y. 5 mo.

Update

Santamed LT - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 983,701 1,129,343 1,015,986 1,538,715 1,874,654 2,020,657 2,181,742 2,426,109
Profit before tax -12,504 31,722 40,822 31,979 -8,774 582 1,458 2,459
Net profit -12,504 28,062 34,671 27,147 -8,774 460 1,024 941
Equity -3,471 24,591 46,262 39,409 5,635 6,095 7,119 8,060
Liabilities 139,374 48,049 57,759 260,291 222,627 456,190 383,932 449,507
Non-current assets 7,901 9,583 11,291 9,222 7,377 4,538 10,790 8,572
Current assets 128,002 63,057 92,730 290,478 220,885 456,758 380,261 447,285
Total assets 135,903 72,640 104,021 299,700 228,262 461,296 391,051 455,857
Taxes paid
STI taxes - - - - - 142,860 140,104 236,681
Social insurance contributions - - - - - 65,316 76,272 88,589
Financial indicators
Revenue change y/y +134.1% +14.8% -10.0% +51.5% +21.8% +7.8% +8.0% +11.2%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -9.2% 38.6% 33.3% 9.1% -3.8% 0.1% 0.3% 0.2%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - 114.1% 74.9% 68.9% -155.7% 7.5% 14.4% 11.7%
Profit margin Net profit margin. Shows the overall profitability of the company. -1.3% 2.5% 3.4% 1.8% -0.5% 0.0% 0.0% 0.0%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. -1.3% 2.8% 4.0% 2.1% -0.5% 0.0% 0.1% 0.1%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - 2.0 1.2 6.6 39.5 74.8 53.9 55.8
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 132,633 109,292 92,362 133,801 136,338 129,668 114,829 124,416

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Santamed LT - Social security debts

From To Debt, €
2026-05-17 2026-06-08 0.02
2026-05-12 2026-05-13 0.02
2026-05-03 2026-05-11 0.01
2026-04-24 2026-04-29 0.01
2026-01-16 2026-01-20 8.72
2026-01-01 2026-01-12 0.31
2025-12-16 2025-12-30 0.31
2025-11-18 2025-12-14 0.31
2025-10-23 2025-11-12 0.31
2025-07-16 2025-07-24 113.02
2025-05-04 2025-05-11 3.04
2025-04-24 2025-04-29 3.04
2025-03-18 2025-03-18 6463.01

Santamed LT - VMI tax arrears

From To Overdue, €
2026-04-10 2026-04-15 986.99
2025-12-18 2025-12-18 1.45
2025-12-17 2025-12-17 2.26
2025-11-21 2025-11-24 2109.76
2025-09-25 2025-09-25 0.24
2025-09-19 2025-09-24 115.0
2025-07-28 2025-08-22 0.42
2025-07-16 2025-07-23 0.42
2025-03-20 2025-03-24 0.01
2025-02-26 2025-03-17 0.31
2025-02-25 2025-02-25 1154.63

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Santamed LT, UAB, a Private Limited Liability Company, operates in the manufacture of other food products n.e.c. In the latest financial year 2025, the company generated revenue of €2.43M, up 11.2% year on year and 20.1% over two years. Profitability remained very limited: net profit was €941 in 2025, after €1.0K in 2024 and €460 in 2023, indicating modest but positive earnings growth against a growing revenue base. Because profit remained small relative to turnover, the reported profit margin stayed at 0.0%. The balance sheet remained tightly leveraged, with total assets of €455.9K, equity of €8.1K and liabilities of €449.5K in 2025. Assets were largely short term, at €447.3K, while long-term assets were €8.6K. The company’s turnover per asset base was strong, with asset turnover of 5.32x, and revenue per employee stood at €127.7K. Overall, Santamed LT showed steady sales expansion in 2023–2025, while profitability and equity remained very thin.